FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF

A fused heterocyclic derivative represented by the general formula (I) (wherein R1 is hydrogen, OH, etc.; R2 is hydrogen, halogeno, or alkyl; R3 an d R4 each is hydrogen, OH, halogeno, etc.; Q is alkylene, etc.; ring A is aryl or heteroaryl; and G is the group represented by the formula (G1) or (G2)...

Full description

Saved in:
Bibliographic Details
Main Authors SHIOHARA, HIROAKI, TERANISHI, HIROTAKA, MURANAKA, HIDEYUKI, FUSHIMI, NOBUHIKO, ITO, FUMIAKI, YONEKUBO, SHIGERU, SHIMIZU, KAZUO, ISAJI, MASAYUKI
Format Patent
LanguageEnglish
French
Published 14.10.2004
Edition7
Subjects
CHEMISTRY
DERIVATIVES THEREOF
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SUGARS
Online AccessGet full text

Cover

More Information
Summary:A fused heterocyclic derivative represented by the general formula (I) (wherein R1 is hydrogen, OH, etc.; R2 is hydrogen, halogeno, or alkyl; R3 an d R4 each is hydrogen, OH, halogeno, etc.; Q is alkylene, etc.; ring A is aryl or heteroaryl; and G is the group represented by the formula (G1) or (G2)), (G1) (G2) a pharmacologically acceptable salt of the derivative, or a prodru g of either. They have excellent inhibitory activity against human SGLT and ar e useful as preventive or therapeutic agents for diseases attributable to hyperglycemia, such as diabetes, postprandial hyperglycemia, impaired glucos e tolerance, complications of diabetes, and obesity.
Bibliography:Application Number: CA20042520436